Parathyroid Hormone Shows Promise for Chronic Back Pain Relief: New Study

Chronic low back pain, a condition affecting millions globally, may soon have a new avenue for treatment thanks to research identifying a key role for parathyroid hormone (PTH) in regulating nerve growth within the spine. A study published in Bone Research suggests that PTH can potentially halt the progression of chronic back pain by reversing abnormal nerve growth, offering a glimmer of hope for those who haven’t found relief through conventional methods.

The Challenge of Chronic Back Pain

Low back pain is remarkably common, impacting people of all ages and placing a substantial burden on healthcare systems. The difficulty in treating chronic cases often stems from the lack of a clearly identifiable structural cause – meaning doctors struggle to pinpoint the exact origin of the pain. This makes long-term, effective treatment particularly challenging. According to the National Institute of Neurological Disorders and Stroke, back pain is one of the most common reasons people visit a doctor. https://www.ninds.nih.gov/health-information/disorders/back-pain

How Parathyroid Hormone Offers a New Approach

The research, led by Dr. Janet L. Crane of Johns Hopkins University School of Medicine, focused on the role of PTH, a hormone naturally produced by the parathyroid glands, which is already used in synthetic form to treat osteoporosis. The team discovered that PTH can reverse the process of pain-sensing nerves growing into areas of the spine where they shouldn’t be. “During spinal degeneration, pain-sensing nerves grow into regions where they normally do not exist. Our findings show that parathyroid hormone can reverse this process by activating natural signals that push these nerves away,” explains Dr. Crane.

The study utilized three different mouse models designed to mimic common causes of spinal degeneration: natural aging, surgically induced instability and genetic predisposition. Mice received daily PTH injections for periods ranging from two weeks to two months, and researchers then meticulously examined spinal tissue using high-resolution imaging, assessing responses to pressure, heat, and movement. The results showed that PTH treatment led to denser, more stable vertebral endplates – the cushions between the spinal discs and vertebrae – and a noticeable reduction in pain sensitivity.

Delving into the Mechanism: Slit3 and Osteoblasts

The researchers didn’t stop at observing the effects of PTH. they sought to understand how it worked. They found that PTH stimulates osteoblasts – the cells responsible for building bone – to produce a protein called Slit3. This Slit3 protein acts as a “guidance signal,” effectively repelling growing nerve fibers and preventing them from invading sensitive areas of the spine.

Laboratory experiments confirmed this mechanism. When nerve cells were exposed to Slit3, their growth was demonstrably stunted and less invasive. Conversely, when Slit3 production was blocked in osteoblasts, PTH’s ability to reduce nerve growth and alleviate pain was eliminated. The team also identified FoxA2, a regulatory protein that triggers Slit3 production in response to PTH, further illuminating the complex hormonal and neurological interplay at play. https://news.google.com/rss/articles/CBMitAFBVV95cUxPYmJPaDJVUzl2Q3E3Nk1makhYencxYkxMSU9VTkNfdmRyZXlnVmh4RVp1Mi16RzY2aHlkdE5LeFd2VENIckpVRXQtVVltbnNoa051ekR0M1FJSHljWUhFSTZJc0YxTlBTSG5IWFdKYnljbFUwVFh0NEtlZGJEVnlNR2YtNFh1Y2JLeGtRMXFCdW1iLVRGbnQxckZEU19oRENoMm16SEJObmlLSHdYZkU4aXBfdlM?oc=5

What This Means for Patients – and What It Doesn’t

While these findings are promising, it’s crucial to remember that this research was conducted on mice. The researchers acknowledge that further studies are needed to determine if PTH-based treatments will have the same effect in humans. However, the study does offer a potential explanation for why some patients receiving PTH for osteoporosis report a reduction in back pain.

It’s essential to understand that this isn’t a cure, and PTH isn’t being proposed as a direct treatment for back pain at this stage. Instead, the research identifies a potential biological pathway that could be targeted with future therapies. The study highlights the complex relationship between bone health and nerve function in the development of chronic pain.

The Path Forward: Clinical Trials and Further Research

Dr. Crane and her team are optimistic about the potential for clinical trials to explore the efficacy of PTH as a disease-modifying and pain-relief treatment for spinal degeneration. The next steps involve carefully designed human studies to assess the safety and effectiveness of PTH in individuals with chronic back pain. These trials will need to account for various factors, including the cause of the pain, the severity of the condition, and individual patient characteristics.

The National Institutes of Health (NIH) supported this research, specifically through the National Institute on Aging. https://news.google.com/rss/articles/CBMib0FVX3lxTE4xUzRkZ3BndjZ5b1FpQW45VDFrUHRtNmhVa0pYdm5vcVlZQmRiQ1hzSkVJYi1NcHhWM2RkeHl5TkRQcWZoanZ6TVpOSnN0d2x2OFRvZ1hvU2ZZTjJVaHBrN3lXNGRncjBRYmF2bWR6SQ?oc=5 This ongoing investment in musculoskeletal research is crucial for developing innovative treatments for debilitating conditions like chronic back pain. Patients experiencing persistent back pain should continue to work closely with their healthcare providers to explore all available treatment options and manage their condition effectively.

About Dr. Janet L. Crane: Dr. Crane is an Associate Professor of Pediatrics at Johns Hopkins University School of Medicine, and Director of the Pediatric Bone Health Program. Her research focuses on metabolic bone diseases and skeletal fragility.